Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib + Trametinib in BRAF-mutated advanced solid tumors (BROAD)
NCT05876806Phase 2Recruiting
- Start
- Jun 2023
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dabrafenib + trametinib and trametinib in solid tumor (advanced stage). Started Jun 2023; status: recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05876806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05876806.